TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh
Brief Summary: The investigators aim to establish the non-inferiority of concomitant administration of measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of measles seroconversion rates. The primary study hypothesis is the measles seroconversion rate as defined by the percentage of children seroconverting to measles with a measles serum antibody concentration of \>=1:120 at 8 weeks post vaccination after the concomitant administration of measles-rubella and rotavirus vaccines is non-inferior to that obtained when measles-rubella vaccine is given alone in children 9 months of age who have received a primary rotavirus vaccine series with the first dose between 6 and 10 weeks and the second at least 4 weeks later and are seronegative for measles antibody in the pre-vaccination sample.


Options:
A: Arm Label: rotavirus vaccine 116E 1 X 10(4); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Arm Label: rotavirus vaccine 116E 1 X 10(5); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Intervention Type: BIOLOGICAL; Name: Oral Rotavirus Vaccine 116E Live Attenuated; Assigned to Arm(s): rotavirus vaccine 116E 1 X 10(4), rotavirus vaccine 116E 1 X 10(5)
B: Arm Label: 1; Type: OTHER; Interventions: Biological: Rotateq vaccine | Intervention Type: BIOLOGICAL; Name: Rotateq vaccine; Assigned to Arm(s): 1
C: Arm Label: measles-rubella and rotavirus vaccines; Type: EXPERIMENTAL; Interventions: Biological: Rotarix vaccine, Biological: measles-rubella vaccine | Arm Label: measles-rubella vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: measles-rubella vaccine | Intervention Type: BIOLOGICAL; Name: Rotarix vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines | Intervention Type: BIOLOGICAL; Name: measles-rubella vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines, measles-rubella vaccine
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression
Brief Summary: This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression.

The first drug, Ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.


Options:
A: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Ketamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam
B: Arm Label: Ketamine 0.1mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 1.0mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Midazolam (Active Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.1mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.2mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 1.0mg | Intervention Type: DRUG; Name: Placebo Midazolam; Assigned to Arm(s): Midazolam (Active Placebo)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1
D: Arm Label: Esketamine; Type: EXPERIMENTAL; Interventions: Drug: Esketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electroacupuncture for Pain Relief in Patients With Nasal Sinus Surgery and Mammaplasty: a Randomized Controlled Study
Brief Summary: The purpose of this study is to verify the intraoperative analgesia of electroacupuncture in patients undergoing selective nasal sinus surgery and mammaplasty.


Options:
A: Intervention Type: DEVICE; Name: Acupressure; Assigned to Arm(s): N/A
B: Arm Label: Electroacupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Non-electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Procedure: non-electroacupuncture | Intervention Type: PROCEDURE; Name: non-electroacupuncture; Assigned to Arm(s): Non-electroacupuncture | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture
C: Intervention Type: DEVICE; Name: Vital-band (R); Assigned to Arm(s): N/A
D: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Acustimulation | Arm Label: Standard treatment group; Type: NO_INTERVENTION; Interventions: Device: Acustimulation | Intervention Type: DEVICE; Name: Acustimulation; Assigned to Arm(s): Acustimulation, Standard treatment group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Online Social Networks for HIV Prevention and Testing
Brief Summary: This study seeks to determine whether social networking technologies can be used to increase HIV prevention and testing.The HOPE (Harnessing Online Peer Education) model seeks to apply a diffusion of innovations style intervention to social media to increase HIV testing.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Voice Reminder (Group A); Type: EXPERIMENTAL; Interventions: Behavioral: Voice Reminder (Group A) | Arm Label: Cash Incentive (Group B); Type: EXPERIMENTAL; Interventions: Behavioral: Cash Incentive (Group B) | Intervention Type: BEHAVIORAL; Name: Voice Reminder (Group A); Assigned to Arm(s): Voice Reminder (Group A) | Intervention Type: BEHAVIORAL; Name: Cash Incentive (Group B); Assigned to Arm(s): Cash Incentive (Group B)
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS text message; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message | Arm Label: SMS text message + Peer Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message + Peer Navigation | Intervention Type: BEHAVIORAL; Name: SMS text message; Assigned to Arm(s): SMS text message | Intervention Type: BEHAVIORAL; Name: SMS text message + Peer Navigation; Assigned to Arm(s): SMS text message + Peer Navigation
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Arm Label: HIV intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: HIV knowledge Intervention | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HIV knowledge Intervention; Assigned to Arm(s): HIV intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Online Social Networks for HIV Prevention and Testing
Brief Summary: This study seeks to determine whether social networking technologies can be used to increase HIV prevention and testing.The HOPE (Harnessing Online Peer Education) model seeks to apply a diffusion of innovations style intervention to social media to increase HIV testing.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders | Intervention Type: BEHAVIORAL; Name: Reminders; Assigned to Arm(s): Reminders
B: Arm Label: HIV intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: HIV knowledge Intervention | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HIV knowledge Intervention; Assigned to Arm(s): HIV intervention Group
C: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine
D: Arm Label: Reminder module (SMS and Phone call); Type: EXPERIMENTAL; Interventions: Behavioral: Reminder module (SMS and Phone call) | Arm Label: Photovoice; Type: EXPERIMENTAL; Interventions: Behavioral: Photovoice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder module (SMS and Phone call); Assigned to Arm(s): Reminder module (SMS and Phone call) | Intervention Type: BEHAVIORAL; Name: Photovoice; Assigned to Arm(s): Photovoice

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Online Social Networks for HIV Prevention and Testing
Brief Summary: This study seeks to determine whether social networking technologies can be used to increase HIV prevention and testing.The HOPE (Harnessing Online Peer Education) model seeks to apply a diffusion of innovations style intervention to social media to increase HIV testing.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
B: Arm Label: MiQuit; Type: EXPERIMENTAL; Interventions: Behavioral: MiQuit | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MiQuit; Assigned to Arm(s): MiQuit
C: Arm Label: HIV intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: HIV knowledge Intervention | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HIV knowledge Intervention; Assigned to Arm(s): HIV intervention Group
D: Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care Treatment | Arm Label: Mobile Health Messaging Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Health Messaging application, Other: Standard of Care Treatment | Arm Label: Focus Group Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile Health Messaging application; Assigned to Arm(s): Mobile Health Messaging Arm | Intervention Type: OTHER; Name: Standard of Care Treatment; Assigned to Arm(s): Control Arm, Mobile Health Messaging Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Cognitive Remediation Treatment in Adolescents With Schizophrenia Spectrum Disorders
Brief Summary: Cognitive Remediation Therapy (CRT) can enhance cognitive performance in schizophrenia improving functional outcome. But most of the studies have involved participants who are in average in their mid 30s, and little is known about the efficacy of CRT in adolescents with early-onset schizophrenia (EOS). The aim of this study is to investigate efficacy of CRT in improving cognitive performance and functional outcome in adolescents with EOS. We expect to find that CRT improves cognitive and functional outcomes in adolescents with schizophrenia.


Options:
A: Arm Label: Cognitive Remediation Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Remediation Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Remediation Therapy; Assigned to Arm(s): Cognitive Remediation Therapy
B: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
C: Arm Label: treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment as usual | Arm Label: Psychoeducation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation group treatment | Intervention Type: BEHAVIORAL; Name: treatment as usual; Assigned to Arm(s): treatment as usual | Intervention Type: BEHAVIORAL; Name: Psychoeducation group treatment; Assigned to Arm(s): Psychoeducation Group
D: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Acclimatization to Hypoxia at Altitude
Brief Summary: In low oxygen environments, such as altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower altitudes (e.g. sea-level). The purpose of this investigation is to study the effects of two drugs that may help people adjust to high-altitude quickly, prevent them from becoming ill and improve their exercise performance. The drugs are Methazolamide and Aminophylline.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide
C: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Acclimatization to Hypoxia at Altitude
Brief Summary: In low oxygen environments, such as altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower altitudes (e.g. sea-level). The purpose of this investigation is to study the effects of two drugs that may help people adjust to high-altitude quickly, prevent them from becoming ill and improve their exercise performance. The drugs are Methazolamide and Aminophylline.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rhodiola crenulata-placebo sequence; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rhodiola crenulata, Drug: placebo | Arm Label: Placebo-Rhodiola crenulata sequence; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rhodiola crenulata, Drug: placebo | Intervention Type: DRUG; Name: Rhodiola crenulata; Assigned to Arm(s): Placebo-Rhodiola crenulata sequence, Rhodiola crenulata-placebo sequence | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo-Rhodiola crenulata sequence, Rhodiola crenulata-placebo sequence
C: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Acclimatization to Hypoxia at Altitude
Brief Summary: In low oxygen environments, such as altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower altitudes (e.g. sea-level). The purpose of this investigation is to study the effects of two drugs that may help people adjust to high-altitude quickly, prevent them from becoming ill and improve their exercise performance. The drugs are Methazolamide and Aminophylline.


Options:
A: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.
Brief Summary: The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.


Options:
A: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
B: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI
C: Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719

Answer: D